Next-Generation PARP Inhibitor (Saruparib) Demonstrates Clinical Benefit in Patients with Homologous Recombination Repair-Deficient Breast Cancer

Drug has higher selectivity for PARP1, improving safety and tolerability.

Saruparib, a selective inhibitor of poly-ADP ribose polymerase 1 (PARP1), demonstrated a promising objective response rate and progression-free survival in patients with certain homologous recombination repair (HRR)-deficient breast cancers, according to results from the phase I/II PETRA trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10 in San Diego.

Login Or Register To Read Full Story